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Abstract 
We describe the preparation, physico-chemical characterization and anti-inflammatory properties 
of liposomes containing the superparamagnetic nanoparticle Nanotex, the fluorescent dye Rho-
damine-100 and omega-3 polyunsaturated fatty acid ethyl ester (ω-3 PUFA-EE), as theranostic 
anti-inflammatory agents. Liposomes were prepared after drying chloroform suspensions of egg 
phosphatidylcholine, hydration of the lipid film with aqueous phases containing or not Nanotex, 
Rhodamine-100 dye or ω-3 PUFA-EE, and eleven extrusion steps through nanometric membrane 
filters. This resulted in uniform preparations of liposomes of approximately 200 nm diameter. 
Extraliposomal contents were removed from the preparation by gel filtration chromatography. 
High Resolution Magic Angle Spinning 1H NMR Spectroscopy of the liposomal preparations 
containing ω-3 PUFA-EE revealed well resolved 1H resonances from highly mobile ω-3 PUFA-EE, 
suggesting the formation of very small (ca. 10 nm) ω-3 PUFA-EE nanogoticules, tumbling fast in the 
NMR timescale. Chloroform extraction of the liposomal preparations revealed additionally the 
incorporation of ω-3 PUFA-EE within the membrane domain. Water diffusion weighted spectra, 
indicated that the goticules of ω-3 PUFA-EE or its insertion in the membrane did not affect the 
average translational diffusion coefficient of water, suggesting an intraliposomal localization, that 
was confirmed by ultrafiltration. The therapeutic efficacy of these preparations was tested in two 
different models of inflammatory disease as inflammatory colitis or the inflammatory component 
associated to glioma development. Results indicate that the magnetoliposomes loaded with ω-3 
PUFA-EE allowed MRI visualization in vivo and improved the outcome of inflammatory disease in 
both animal models, decreasing significantly colonic inflammation and delaying, or even reversing, 
glioma development. Together, our results indicate that magnetoliposomes loaded with ω-3 
PUFA-EE may become useful anti-inflammatory agents for image guided drug delivery. 
Key words: Magnetoliposomes, ω-3 poly-unsaturated fatty acid ethyl ester, Superparamagnetic 
nanoparticle, MRI, Image guided drug delivery. 
Introduction 
Inflammatory lesions are associated to the most 
prevalent and morbid pathologies in developed 
countries including atherosclerosis [1, 2], neuro-
degeneration [3, 4] diabetes or obesity [5, 6] and can-
cer [7-9], among others. Decreases in the inflamma-








sion and improve patient´s quality of life, as well as to 
enhance recovery [7, 9]. With this aim, a variety of 
anti-inflammatory drugs have been proposed as ad-
juvant therapies for the different diseases, including 
mainly steroidal or non-steroidal treatments [10-12]. 
However, anti-inflammatory therapies demand the 
use of relatively large doses of the free drugs and in-
evitably end up developing, a collection of adverse 
secondary effects that preclude continuation of the 
treatment [13, 14]. On these grounds, methods to im-
prove the efficiency of anti-inflammatory drug deliv-
ery to the lesion, decreasing the dose and increasing 
its selectivity and efficacy, entail considerable im-
portance in a wide spectrum of diseases. 
Liposomes have been proposed previously as 
novel nanotechnology formulations to improve drug 
delivery to a variety of inflammatory diseases [15-17]. 
Targeting of the inflammatory region may be 
achieved using, either active or passive approaches. 
Active targeting involves the use vectorial reagents 
embedded in the liposomal membrane that recognize 
epitopes of the target lesion [18]. Passive targeting 
refers to the passive accumulation of the liposomes in 
the inflamed regions because of the Enhanced Per-
meability Retention (EPR), an effect derived from 
their relatively increased capillary permeability and 
limited clearance [19]. In both targeting strategies, it 
becomes difficult to visualize non-invasively if the 
liposomal preparation has arrived to the target tissue 
and many times, only indirect measurements of the 
inflammation size or volume provide an index of the 
anti-inflammatory effect. It would become then very 
useful, to be able to locate directly and non-invasively 
the presence of the drug loaded liposomes in the le-
sion. Liposomes are optimal structures for this pur-
pose, since they can be prepared to contain in their 
lumen, in addition to the anti-inflammatory drug, a 
variety of imaging probes including radioactive, flu-
orescent or superparamagnetic agents, among others 
[20-22]. The liposomal lumen can be loaded with wa-
ter-soluble drugs, maintained in solution in the lu-
men, or lipid-soluble drugs, thought to incorporate 
spontaneously in the bilayer membrane [23, 24]. This 
approach is known as image guided drug delivery, 
representing currently a powerful strategy to diag-
nose and treat inflammatory diseases [25-28]. 
Important anti-inflammatory effects have been 
reported using preparations of omega-3 fatty acids 
[29-35], a kind of long chain polyunsaturated fatty 
acids (PUFAs) mainly present in fish oils and used as 
dietary supplement. Omega-3 PUFAs allow pro-
longed anti-inflammatory treatments without the 
appearance of the deleterious secondary effects of 
alternative steroidal or non-steroidal drugs [14, 36], 
operating simultaneously on a variety of targets of the 
inflammatory cascade. 
In this work we report on a successful protocol to 
encapsulate ω-3 PUFA [37] containing in addition, 
either or both, the novel Nanotex superparamagnetic 
nanoparticle [38] or the Rhodamine-100 dye, thus al-
lowing in vivo monitorization using magnetic reso-
nance imaging or fluorescence. These advanced 
theranostic preparations maintain completely the 
therapeutic potential of free ω-3 PUFA, potentiated 
additionally with highly versatile multimodal imag-
ing capabilities. We demonstrate here the an-
ti-inflammatory effects of these preparations in vivo, in 
animal models of colonic and oncologic inflammation. 
Materials and Methods 
Preparation of Nanotex 
Nanotex is a superparamagnetic nanoparticle 
containing a magnetite (Fe3O4) core with poly(acrylic) 
acid coating. Magnetite (Fe3O4) nanoparticles were 
prepared by the co-precipitation of Fe3+ and Fe2+ ions 
(molar ratio 2:1) at 25 °C and a concentration of 0.3 M 
iron ions with ammonia solution (29.6%) at pH 10 in 
an inert atmosphere, followed by hydrothermal 
treatment at 80 °C for 30 min. For the binding of 
poly(acrylic acid) (PAA), 100 mg of Fe3O4 nanoparti-
cles were first mixed with 2 mL of buffer A (0.003 M 
phosphate, pH 6) and 0.5 mL of carbodiimide solution 
(0.025 g/mL in buffer A). After being sonicated for 10 
min, 2.5 mL of PAA solution (60 mg/mL in buffer A) 
was added and the reaction mixture was sonicated for 
another 30 min. Finally, the PAA-coated Fe3O4 nano-
particles were recovered magnetically, washed with 
water twice and dialyzed against a buffer saline solu-
tion. Nanotex preparations were highly water soluble, 
stable for several months, and depicted uniform di-
ameters smaller than 15 nm [38]. 
Preparation and characterization of liposomes 
Lipid film hydration and extrusion method 
Liposomes were prepared essentially using the 
film hydration method [17, 39, 40]. Briefly, 20 mg (26 
µmol) of L-α-phosphatidylcholine (PtdCho, Avanti 
Polar Lipids Inc. 840051P, Alabaster, Alabama, USA) 
were dissolved in 2 mL of chloroform (Merck, Darm-
stad, DE K36897545). The solution was placed in a 
round bottom flask and subjected to rotary evapora-
tion (Heindolph Instruments, Schwabach, DE) for 
sixty minutes (280 rpm, 474 mBar, 40 °C). The lipid 
film formed after chloroform evaporation was further 
rotated under the same conditions to remove chloro-
form traces. Then, the dried lecithin film was rehy-
drated with 5 mL of water (containing or not the ac-
tive principle and imaging probes) and rotated 60 
minutes at atmospheric pressure and 50 °C. This 




process generates a heterogeneous suspension of lip-
osomes of different sizes containing or not the active 
principles and imaging probes in their lumen or out-
side as delivered with the hydration buffer. To ho-
mogenize the size distribution, the liposomal suspen-
sion was extruded eleven times (Northen Lipids, 
Burnaby, CA) under nitrogen pressure through a 200 
nm membrane (Whatman, GE Healthcare, Fairfield, 
Connecticut, US) maintaining the extrusor tempera-
ture at 50 °C. The resulting suspension containing 
homogenous liposomes, loaded or not with the se-
lected imaging agent and ω-3 PUFA ethyl esther (ω-3 
PUFA-EE), was stored at 4 °C until further utilization. 
Figure 1A provides a schematic description of the 
process.  
We prepared liposomes encapsulating either 
suspensions of (i) buffer alone, (ii) Nanotex super-
paramagnetic nanoparticle (0.5 mg Fe/mL, Solutex 
S.L., Alcobendas, ES) as MRI detectable probe, (iii) 
Nanotex and ω-3 PUFA-EE (0.1% v/v final volume, 
0.75 mM, 95% w/v eicosapentanoic acid ethyl ester, 
Solutex S.L., Alcobendas, ES) as theranostic an-
ti-inflammatory agents detectable by MRI, or (iv) 
Nanotex with Rhodamine-100 chloride (10 mg/mL 
Sigma Aldrich, Barcelona, ES) as a novel hybrid im-
aging agent detectable by MRI and fluorescence. 
 
 
Figure 1. Preparation and characterization of liposomes. A:Liposomes are prepared from egg yolk lecithin, containing or not ω-3 PUFA-EE, Nanotex or 
Rhodamine-100 by the film hydration method [39]. A solution of chloroform and lecithin is rotated under vacuum to remove chloroform, depositing a thin lecithin 
film covering the round bottom flask. Hydration of this film with aqueous buffer results liposomes of heterogeneous sizes and different numbers of layers. Nanotex 
(black circles), ω-3 PUFA-EE (yellow circles) or Rhodamine-100 (red circles) may be added to the buffer, resulting in their intraluminal encapsulation. Some residual 
Nanotex, ω-3 PUFA-EE or Rhodamine-100 may remain in the extraliposomal space. Repeated extrusions (x11) result in crude homogeneous suspensions of 
liposomes loaded or not with added components in their lumen, but present also in the extraliposomal space. These may be removed later after a purification process, 
normally based in size exclusion chromatography (Sephadex G50) or centrifugal ultrafiltration through filters of controlled pore size. B: Absorption (turbidity) peaks 
at 380 nm from the column fractions loaded with a sample of liposomes with Nanotex and ω-3 PUFA-EE. Note that the elution profile presents an initial peak 1 
corresponding to large Nanotex particle aggregates not encapsulated in the liposomes, followed by the most prominent peak 2 derived from liposomes containing 
PUFA-EE goticules and Nanotex, and extraliposomal free Nanotex particles (peak 3) or PUFA-EE goticules (peak 4). Representative DLS of a suspension of empty 
liposomes (C) and a suspension of liposomes loaded with ω-3 PUFA-EE (D). Black arrows indicate the size of smaller or larger aggregates of free ω-3 PUFA-EE. 





The ultrafiltration method separates the crude 
liposomal preparation in two fractions, the sediment 
containing the liposomes, and the ultrafiltrate con-
taining mainly the extraliposomal medium. This is 
achieved by forcing the crude liposomal preparation 
to pass through a filter of controlled pore size, under 
centrifugal acceleration. For this purpose, we used 
molecular size filters with a pass of 300 KDa (Vivaspin 
6, MWCO 300 KDa, Vivaproducts, Littleton, MA, US). 
The centrifuge used was J-6B (Beckman Coulter, 
L’Hospitalet de Llobregat, ES) with centrifugation 
conditions of 2891 G (3900 rpm, 20 °C, 1 hour). After 
the centrifugation, the absorption spectra (200 – 600 
nm) of the sediment and the ultrafiltrate was obtained 
to determine the presence of PUFA- EE goticules us-
ing multiwall plates in a vertical spectrofluorometer 
(Synergy, Biotek, Winooski, VT, US). 
Size exclusion chromatography 
Size exclusion chromatography separates the 
components of a heterogeneous sample according to 
their size or molecular weight. Those components 
larger than the pores of the matrix (Sephadex G-50, 
Sigma-Aldrich, Alcobendas, ES) are excluded from 
the exchange and proceed faster to the chromato-
graphic front, while those components with smaller 
size than the matrix pore are temporally retained, 
with longer elution times for the smaller molecules 
[39].  
The column dimensions were 1.8 x13 cm. Two 
grams of Sephadex G50 (swell capacity 1 g/9 mL) 
were hydrated with 40 mL of H2O Milli-Q (4 °C, 16 
hours). After Sephadex hydration, the column was 
charged and compressed with H2O Milli-Q (250 mL), 
stabilizing the flux to 0.3 mL/min. Then, the Se-
phadex column was presaturated with an empty lip-
osomes preparation to minimize non selective ad-
sorption. Then, 300 μL of the crude liposomal prepa-
ration were added to column head and run (0.3 
mL/min) with 50 mL of H2O Milli-Q. Fractions of the 
eluate were collected automatically (400 μL/90 sec, 
Biorad 210, BioRad Laboratories, Madrid, ES) and 
analyzed spectrophotometrically on a vertical plate 
reader (Synergy, BioTek, VT, US).  
Figure 1B shows a representative elution profile 
from the gel filtration chromatography of a crude 
preparation of liposomes containing Nanotex and ω-3 
PUFA-EE as monitored by measurements of absorb-
ance (turbidity) at 380 nm. The first peak observed 
(peak 1), co-eluting with the solvent front, corre-
sponds to large aggregates of extraliposomal Nano-
tex, since it is observed also when running lipo-
some-free Nanotex preparations. The second peak 
(peak 2) corresponds to liposomes loaded with ω-3 
PUFA-EE and Nanotex. Finally, the two peaks eluting 
later, correspond to small extraliposomal free indi-
vidual Nanotex particles (peak 3) and external goti-
cules of ω-3 PUFA-EE (peak 4) not entrapped within 
the liposome, since both co-elute with the corre-
sponding standards, respectively. The comparison of 
the absorbance (turbidity) measurements between the 
crude preparation and the purified liposomal frac-
tions lead us to the conclusion that liposomes encap-
sulate approximately 30% of the added ω-3 PUFA-EE 
or close to 100% of the added Nanotex. 
Dynamic Light Scattering 
The size of liposomes (Figure 1C, 1D) was 
measured by Dynamic Light Scattering (DLS, 
DynaPro MS/X Wyatt Inc., Dernbach, DE) essentially 
as described by Berne et al. and Hallett et al. [41, 42]. 
A dilution 1:10 of the original samples in water was 
placed in a quartz cuvette inside the apparatus to 
perform the light scattering measurement.  
1H High Resolution Magic Angle Spinning (HRMAS) 
1H HRMAS spectroscopy was performed using a 
Bruker Avance 11.7 T instrument equipped with a 
High Resolution Magic Angle Spinning (HRMAS) 
accessory, interfaced with a Linux driven Paravision 
IV console (Bruker BIOSPIN, Ettlingen, DE). Briefly, 
samples were dissolved in deuterated water (25 μL, 
99.2% 2H, Apollo Scientific Limited, Stockport, UK) or 
deuterated chloroform (25 μL, 99.8% 2H, Scharlau, 
Barcelona, ES) containing 1 mM TMS (tetramethyl 
silane, Scharlau, Barcelona, ES) or 1 mM TSP (trimetil 
sylil 2, 2’, 3, 3’ tetradeutero sodium propionate) as 
chemical shift references (0 ppm), respectively. Sam-
ples were placed in 50 µL zirconium rotors, inserted in 
the HRMAS probe and allowed 10 min for tempera-
ture equilibration. Water suppressed 1H HRMAS 
spectra (4 °C, 4000 Hz) were acquired using the 
Carr-Purcell-Meiboom-Gil sequence with π/2 pulses, 
spectral width 10 kHz, acquisition time 0.41 sec, D1=1 
sec, and 72 π pulses equally separated τ=1 ms. Spec-
tral processing used 1 Hz exponential line broadening 
function applied in the time domain data prior to 
Fourier Transformation [43]. 
2D COSY spectra were acquired using the se-
quence π/2-TD-π/2-acquire, with 2048 TD increments 
in the f1 dimension and an acquisition time of 0,21s in 
the f2 dimension. Cross-Peak correlations were ana-
lyzed in contour plots obtained after two dimensional 
Fourier transformations. 
1H NMR DOSY (Diffusion-Ordered NMR Spec-
troscopy) spectra of liposomal suspensions were ac-
quired in a 400 MHz Bruker AVANCE III spectrome-
ter (Bruker BIOSPIN, Ettlingen, DE) using a 1H selec-
tive probe and 5 mm NMR tubes. The spin-echo 




Stejskal-Tanner sequence, π/2-∆-π-∆-acquire, was 
used with ∆ values of 20, 50 and 100 ms and sixteen 
linear increments of the diffusion weighting gradient 
ranging from 2% to 95% of the maximal gradient 
strength. [43]. 
Water Relaxivity 
We investigated the effect of magnetoliposomes 
on the T1 and T2 magnetic relaxation times of the wa-
ter molecules of the suspension, to assess their poten-
tial usefulness as imaging agents for MRI detection. T1 
and T2 relaxation times of magnetoliposomes were 
investigated in two different liposomal samples, con-
taining or not the superparamagnetic particle Nano-
tex (0.5 mg Fe/mL). Dilutions of the original suspen-
sions to 50% (v/v) and 25% (v/v) of the initial con-
centration were used to generate the relaxation vs. 
concentration profiles. r1,2 relaxivity are the relaxation 
rates (1/T1,2) of the water protons and can be calcu-
lated by linear regression fittings of the r1,2 values to 
the Fe concentration using the expression 
r1,2= r01,2+ r11,2 [Fe] 
where r1,2 represent the relaxivity in r1 or r2 
(s-1·mmol-1); r01,2, represents the relaxation rate of the 
water protons in the absence of magnetoliposomes, 
r11,2 the relaxation rate of the water protons in the 
presence of different concentrations of magnetolipo-
somes, and [Fe] the mM concentration of Fe in the 
magnetoliposomal suspension. Briefly, T1 or T2 values 
of all samples (37 °C) were measured using the inver-
sion recovery sequence or Carr-Purcell-Meiboom-Gill 
(CPMG) sequences using a Bruker Minispec 1.5 Tesla 
time domain spectrometer (Bruker BIOSPIN, Et-
tlingen, DE) [44].  
Fluorescence 
We investigated the fluorescent properties of 
magnetoliposomes labeled with Rhodamine-100 
chloride both in vitro and in vivo using an in vivo 
IVIS-Lumina system (Perkin Elmer, Waltham, Mas-
sachusetts, USA) [45]. In vitro and in vivo fluorescence 
images were acquired using a Green Fluorescent 
Protein filter (GFP, 445-490 nm excitations, 515-575 
nm emission) during sixty seconds of exposure time. 
For the in vitro studies, three samples of liposomes 
containing or not the nanoparticle (25 mg Fe/mL) and 
the fluorescent dye (10 mg/mL), at different concen-
trations (18.75 mg Fe/mL, 12.5 mg Fe/mL, 6.25 mg 
Fe/mL for the nanoparticle and 7.5 mg/mL, 5 
mg/mL, 2.5 mg/mL for Rhodamine-100 were placed 
in 96-well plate and scanned. For the in vivo studies, 
CD1 adult mice (30 g body weight) were anesthetized 
in a ventilated chamber with a mixture of oxygen and 
isofluorane (2%, Isoflo, Esteve, Barcelona, ES) and 
maintained on it during the scanning period. Images 
were acquired as indicated above, five minutes before 
and three minutes after the i.p. injection (200 μL) of 
the liposomal preparations. 
In vivo evaluation of anti-inflammatory activity 
Animal Models of Inflammation and experimental 
design 
All animal procedures were approved by the 
corresponding institutional ethical committee 
(INCSIC) and were performed in accordance with 
Spanish (law 32/2007) and European regulations (EU 
directive 86/609, EU decree 2001-486). Mice were 
housed in cages containing three or four animals per 
cage, under controlled temperature (23 °C) and hu-
midity (47%) conditions and twelve hours light/dark 
cycles (8h, lights on). 
A convenient model of colonic inflammation was 
induced in adult male C56BL6 mice (30 g body 
weight, Charles River, L´Arbresle, FR) through the 
administration of Dextran Sulfate sodium salt (DSS, 
Leti, Barcelona, ES) in the drinking water (3.5% w/v) 
during 5 days [46]. Briefly, two groups of mice re-
ceived DSS treatment for five days and were injected 
in the tail vein (100 µL) with Phosphate Buffered Sa-
line (n=6, Group 1), or Magnetoliposomes containing 
ω-3 PUFA-EE (n=6, Group 2) once during the first 
three days. The evolution of the body weight was 
followed daily in each mouse until the fifth day when 
the animals were investigated by MRI. For this pur-
pose, mice were injected i.p. with 100 µL of 
Gd(III)DTPA (0.1 M) just before coronal T1w images 
were acquired from the rectal zone of each mouse. 
Colonic inflammation was measured by the thickness 
of the rectal wall. After the MRI experiment, the ad-
ministration of DSS was stopped and normal drinking 
water was administered to all mice, following their 
recovery in body weight until day 10th after DSS 
treatment initiation. 
The model of oncologic inflammation was in-
duced in CD1 mice (Charles River, L´Arbresle, FR) 
through the stereotaxic implantation of approxi-
mately 106 C6 glioma cells in the caudate nucleus of 
the mouse brain [47]. Fifteen days after the implanta-
tion, the tumor had proliferated reaching diameters in 
the range 5-15 mm. Five different treatments were 
applied intravenously on day 15th after implantation: 
Group 3 (n=4) received saline administrations only, 
Group 4 (n= 4) received a preparation of empty lipo-
somes, Group 5, (n=4) received preparations of Mag-
netoliposomes without ω-3 PUFA-EE (100 μL) and 
Group 6 (n=4) preparations of Magnetoliposomes 
with PUFA-EE (100 μL), respectively. The growth of 
the glioblastoma after treatment was followed 
non-invasively in the same mouse on the day of 




treatment initiation (Day 0) and three (Day 3) or six 
days (Day 6) after by T1w (Gd(III) enhanced) and T2w 
MRI.  
We considered using administrations of free ω-3 
PUFA-EE as controls for the liposomal administra-
tions in both models. However, the need to formulate 
stable aqueous emulsions of ω-3 PUFA-EE micelles 
for intravenous administration, and the different 
physico-chemical and pharmacokinetic properties 
between micelles and liposomes limited the selection 
of free ω-3 PUFA-EE as control, favoring its liposomal 
formulation. 
Magnetic Resonance Imaging 
All MRI examinations were performed using a 7 
Tesla horizontal magnet (16 cm bore) interfaced with 
a Bruker AVANCE III radiofrequency console oper-
ated through a Linux platform running Paravision V 
software (Bruker Biospin, Ettlingen, DE). 
The colon inflammation model was explored 
with T1 images using a Multi Slice Multi Echo (MSME) 
sequence, TE=10.643 ms, TR=521 ms, 3 averages, axial 
orientation, 22 slices, slice thickness 1.5 mm, interslice 
distance 1.5 mm, field of view 3.8 cm.  
The glioma model was investigated with T1 and 
T2 weighted images. T2 images were acquired using a 
Rapid Acquisition with Relaxation Enhancement 
(RARE) sequence, TE=14.77 ms, TR=2500 ms, 6 aver-
ages, axial direction, 14 slices, slice thickness 1 mm, 
interslice distance 1 mm, field of view 2.3 cm. T1 im-
ages were acquired essentially using the similar con-
ditions as for colonic inflammation with TR=350 ms, 
14 slices, slice thickness 1 mm, interslice distance 1 
mm, field of view 2.3 cm.  
T1 images were always obtained after the i.p. 
administration of 100 μL of Gd(III)DTPA (0.1 M, 
Magnevist, Bayer Schering, Berlin, DE). 
Statistical Analysis 
Comparisons used the mean and standard devi-
ation of all data from each group and the t-student test 
to assess significance (p<0.05). Statistical analysis was 
done using SPSS software (IBM, New York, NY, US). 
Results 
Properties of the liposomal preparations. 
Dynamic Light Scattering 
The protocol for liposomal preparation origi-
nates a suspension of liposomes with homogenous 
size determined by the extrusion pore of the mem-
brane. We determined experimentally the liposomal 
size by Dynamic Light Scattering (DLS). Figures 1C 
and 1D show representative results of size measure-
ments by DLS in liposomal preparations without, or 
with, ω-3 PUFA-EE, respectively. DLS analysis of 
liposomes without ω-3 PUFA-EE showed 200 nm 
diameter vesicles only, corresponding well with the 
200 nm filter used in the extrusion process. The lipo-
somal preparations containing ω-3 PUFA-EE showed, 
in addition to the expected 200 nm liposomal parti-
cles, larger particles of approximately 7000 nm. These 
microparticles accumulated with time at the top of the 
suspension as a lipid layer and could be easily re-
moved from the preparation before further use. 
Smaller size goticules of approximately 20-30 nm 
could also be detected by DLS. 
Magnetic Resonance Spectroscopy 
To elucidate the nature of the incorporation of 
ω-3 PUFA-EE into the liposomal suspensions we im-
plemented a study using High Resolution Magic An-
gle Spinning 1H Magnetic Resonance Spectroscopy 
(HRMAS). 
Figure 2 shows representative 1H HRMAS spec-
tra from aqueous (Figure 2A, 2C) or chloroform (Fig-
ure 2B, 2D) suspensions of empty liposomes (left 
panels) and liposomes loaded with ω-3 PUFA-EE 
(right panels). The spectra of the chloroform suspen-
sions show clearly resolved resonances from the 
magnetically different protons of 
L-α-phosphatidylcholine (PtdCho) and eicosapen-
taenoic acid (EPA, see Scheme 1 for the corresponding 
chemical structures). Complete assignments were 
achieved using literature values and confirmed ex-
perimentally by 2D COSY spectroscopy (Table 1) [48, 
49]. The comparison of 1H HRMAS spectra from 
aqueous suspensions of empty liposomes and lipo-
somes containing ω-3 PUFA- EE demonstrates im-
portant differences. In particular, the 1H HRMAS of 
empty liposome suspensions (Figure 2A) shows only 
small resonances from sufficiently mobile methyl (#1, 
Table 1) and methylene (#2, Table 1) protons of the sn1 
and sn2 fatty acyl chains from 
L-α-phosphatidylcholine, most probably those locat-
ed far away from the choline headgroup and closer to 
the center of the bilayer [50]. However, the motional 
restrictions of the bilayer arrangement impose the 
broadening and virtual disappearance of most phos-
phatidylcholine resonances, including particularly 
those of the choline headgroups (#6, Table 1) which 
are clearly observed in chloroform suspensions (Fig-
ure 2B, arrow) but not in aqueous suspension (Figure 
2A, arrow). The insert in Figure 2A, illustrates the 
typical bilayer structure adopted by PtdCho mole-
cules in liposomes with the choline headgroups ori-
ented towards the external and internal aqueous in-
terfaces. The insert in Figure 2B shows the PtdCho 
molecules in chloroform suspension adopting either 
the unimolecular or inverted micelle arrangements 




with the sn1 and sn2 chains oriented towards the sol-
vent. 
The incorporation of ω-3 PUFA-EE (red mole-
cules) into liposomes originates important spectral 
changes. Notably, most resonances of ω-3 PUFA-EE 
observed in chloroform (Figure 2D) become now ob-
servable in the aqueous suspension (Figure 2C). This 
means that the dynamics of ω-3 PUFA-EE are similar 
in aqueous and chloroform suspensions, indicating 
that ω-3 PUFA-EE may be present as stable nanogot-
icules in both cases. These findings were confirmed by 
the DLS measurements (Figure 1D) which revealed 
clearly the presence of sufficiently small, fast tum-
bling, PUFA-EE nanogoticules of approximately 30 
nm diameter (see red nanogoticule in the Insert Figure 
2C).  
However, nanogoticule formation may not be 
the only form of ω-3 PUFA-EE integration in the lip-
osomes. Interestingly, note that resonance 20 in chlo-
roform (Figure 2D), originated from the olefin protons 
(Table 1), is approximately three times higher than 
resonance 19 corresponding to the α-methylene pro-
tons of the ester group. Notably, the relative intensity 
of resonance 20 as compared to resonance 19, de-
creases drastically in the aqueous suspension (Figure 
2C), suggesting a significant degree of immobilization 
of the olefinic protons from ω-3 PUFA-EE under these 
conditions. This finding is indeed compatible with a 
partial integration of the ω-3 PUFA-EE in the liposo-
mal bilayer, a process involving the formation of an 
α-helical structure stabilizing the chain of conjugated 
double bonds within the membrane, resulting in par-
tial immobilization and 1H NMR invisibility [51, 52]. 
This is illustrated in the insert of Figure 2C by the red 





Figure 2. Characterization of liposomes loaded with ω-3 PUFA-EE by Magnetic Resonance Spectroscopy. Representative HRMAS spectra (500.13 
MHz, 4 °C, 4000 Hz rotation) of aqueous (A, C) and chloroform (B, D) suspensions from empty liposomes (A, B) and from liposomes loaded with ω-3 PUFA-EE (C, 
D). Resonance numbers refer to the assignments indicated in Table 1 and the structures depicted in Scheme 1. Inserts A and B depicts schematically the organization 
of PtdCho molecules (blue) in the bilayer structure of aqueous liposomal suspensions or in the chloroform suspension as individual PtdCho molecules or inverted 
micelles with the choline headgroups oriented inwards. Inserts C or D illustrate the localization of ω-3 PUFA-EE inserted in the membrane or nanogoticules in the 
lumen of aqueous liposomal suspensions, or the inverted micelles and free molecules of PtdCho and ω-3 PUFA-EE in chloroform suspensions, respectively. 





Scheme 1. Chemical Structures of PtdCho (top, blue protons) and ω-3 PUFA-EE (bottom, red protons). 
 
Table 1. Assignments of phospholipid and ω-3 PUFA-EE 1H NMR 
resonances in water and chloroform suspensions. 
 Resonance 
number 
Assignment a) δHDO b) δCDCl3 c) 
Liposomes 1 H16, H53 0.9 0.89-0.86 (m) 
2 H17-28, H38-41, H47-52 1.32 1.25 (m) 
3 H29, H37 n.o. d) 1.57 (m) 
4 H42-46 n.o. d) 2.02 (m) 
5 H30, H36 n.o. d) 2.34-2.26 (dt) 
6 H8, H10, H11 n.o. d) 3.28 (t) 
7 H6 n.o. d) 3.77 (t) 
W Water 4.79 - 
8 H12 n.o. d) 4.05 (m) 
9 H14 n.o. d) 4.13 (m) 
10 H5 n.o. d) 4.37 (m) 
11 H15 n.o. d) 5.23 (m) 
12 H43, H45 n.o. d) 5.33 (m) 
ω-3 PUFA-EE 13 H23 1.03 0.97 (t) 
14 H1 1.27 1.25 (t) 
15 H6 1.73 1.7 (q) 
16 H7, H22 2.19-2.14 2.32-2.07 (m) 
17 H5 2.32 2.3 (t) 
18 H10, H13, H16, H19 2.9-2.87 2.85-2.8 (m) 
19 H2 4.12 4.12 (t) 
W Water 4.79 - 
20 H25-34 5.46-5.40 5.38-5.30 (m) 
a) Resonances 1-20 in Figure 2 are assigned to specific protons of the corresponding 
PtdCho and ω-3 PUFA-EE molecules (see Scheme 1 for proton numbering). 
b) Chemical shifts are measured in ppm and referenced to TSP at 0 ppm. 
c) Chemical shifts are measured in ppm and referenced to TMS at 0 ppm. 
d) The resonances marked with “n.o.” are not observable by high resolution 1H HRMAS 
because of dynamical restrictions in the bilayer. 
 
The above mentioned experiments do not clarify 
the intraluminal or extraliposomal localization of the 
nanogoticules. To investigate this aspect we per-
formed Diffusion Weighted Spectroscopy experi-
ments (DOSY, Figure 3) [53]. This approach measures 
the Apparent Diffusion Coefficient of water (ADC) in 
the liposomal preparation. According to the Einstein´s 
principle the ADC is inversely proportional to the 
number of molecular obstructions that the water 
molecule would find along its random mean diffu-
sional path [54]. ADC measurements under these 
conditions are known to be dominated by the contri-
bution of the extraliposomal volume and if goticules 
would be present there at a significant proportion, one 
would expect a decrease in the observed ADC. In 
contrast, if goticules would be located inside the lip-
osomes, no additional obstructions would be found, 
because of the small contribution of the lumen space 
to total volume of the suspension, and consequently, 
very similar ADC´s would be measured in the pres-
ence and absence of  ω-3 PUFA-EE. We found no sig-
nificant differences in the water ADCs values between 
both preparations at the three diffusion times inves-
tigated, suggesting that the fatty acids ester 
nanodroplets do not increase significantly the molec-
ular obstructions to water movements. Since the 
ADCs are primarily dominated by those of the ex-
traliposomal volume, our results suggest that most 
PUFA-EE goticules are localized in the intraluminal 
space. 
 
Figure 3. Characterization of PUFA-EE nanogoticule localization. 1H 
NMR DOSY (400,7 MHz, 22 °C) spectra of translational water diffusion in 
liposomal suspensions at different diffusion times ∆. Spectra were obtained from 
liposomal suspensions loaded (top panels) or not (bottom panels) with ω-3 
PUFA-EE, with ∆ of 100 ms (left), 50 ms (center) and 20 ms (right). Note that 
the presence of ω-3 PUFA-EE does not decrease significantly the water ADC at 
any of the diffusion times investigated, suggesting primarily an intraluminal 
location of the goticules. 




This could be directly demonstrated by the ul-
trafiltration experiments in which the goticules of ω-3 
PUFA-EE model suspensions passed easily and quite 
completely the 300 kD filters, while the suspensions of 
liposomes containing ω-3 PUFA-EE did not passed 
through filters of identical dimensions, retaining most 
of the PUFA-EE goticules. This confirmed that  ω-3 
PUFA-EE goticules are predominantly intraluminal as 
indicated by the water ADC measurements. 
Taking together these evidences allow for the 
conclusion that liposomal loading with ω-3 PUFA-EE, 
involves both, the formation of nanogoticules located 
in the liposomal lumen as well as the integration of 
ω-3 PUFA-EE within the liposomal bilayer. 
Magnetic relaxation properties 
We investigated the T1 and T2 magnetic relaxa-
tion properties of water molecules in suspensions of 
liposomes, containing or not Nanotex. Tables 2 and 3 
summarize these results. 
Table 2 shows the values of the T1 water relaxa-
tion time in liposome suspensions containing or not 
Nanotex in three successive dilutions of the initial 
concentration. The T1 relaxation value is shortest for 
the highest Nanotex concentration, increasing ap-
proximately linearly when suspensions are further 
diluted, giving a relaxivity value r1 of 6.26 mM-1s-1. 
The same situation is observed with empty liposomes, 
albeit with a much smaller slope for the increase in T1 
relaxation time due to the absence of the superpara-
magnetic nanoparticle.  
Table 3 shows the results of T2 water relaxation 
measurements in the different samples. T2 values for 
the original sample with Nanotex depicted approxi-
mately one thousand times faster relaxation than the 
empty liposomes (Table 3). The T2 relaxation value is 
shortest for the highest Nanotex concentration and 
increases approximately linearly when the liposomal 
suspensions are diluted, giving a relaxivity value r2 of 
64.6 mM-1s-1. The same situation is observed with 
empty liposomes, albeit with a much lower increase of 
T2 relaxation upon dilution and significantly smaller 
relaxivity. In summary, the relaxivity value r1 in-
creases from 0.55 mM-1s-1 for free Nanotex [38] in 
suspension to 6.26 mM-1s-1 for Nanotex encapsulated 
in liposomes. In the case of r2, the value of 88.97 
mM-1s-1 for free Nanotex [38] in solution decreases to 
64.61 mM-1s-1 for encapsulated Nanotex. 
Fluorescence in vitro and in vivo 
The capacity of liposomes as optical biomarkers 
was tested using in vitro and in vivo fluorescence. 
Figure 4 summarizes the results obtained in vitro and 
in vivo with liposomes containing or not Nanotex, and 
labeled fluorescently with Rhodamine-100. 
 
Table 2. T1 values of aqueous liposomal suspensions containing 
or not Nanotex in decreasing concentrations. 
Suspension type /dilution a) T1 (ms) b) 
x1 x1/2 x1/4 
Liposomes w/ nanoparticles 17.3 ± 0.0 34.2 ± 0.1 64.1 ± 0.1 
Liposomes w/o nanoparticles 2161.7 ± 154.6 2207.3 ± 107.9 2955.0 ± 7.1 
a) The dilutions (v/v) of the liposomal preparations correspond to the original liposomal 
suspension (5.26 mM PtdCho, x1), 50% (x1/2) or 25% (x1/4). In the liposomal preparations 
containing Nanotex these dilutions correspond to iron concentrations of 0.5 mg Fe/mL, 
0.25 mg Fe/mL and 0.125 mg Fe/mL. 
b) T1 values were determined at 1.5 Tesla (22 °C, Bruker Minispec, Rheinstetten, DE) using 
the inversion recovery sequence. 
 
Table 3. T2 values of aqueous liposomal suspensions containing 
or not Nanotex in decreasing concentrations. 
Suspension type /dilution a) T2 (ms) b) 
x1 x1/2 x1/4 
Liposomes w/ nanoparticles 1.7 ± 0.0 3.5 ± 0.0 6.6 ± 0.0 
Liposomes w/o nanoparticles 1138.3 ± 34.6 1034.3 ± 6.1 2228.2 ± 0.1 
a) The dilutions (v/v) of the liposomal preparations correspond to the original liposomal 
suspension (5.26 mM PtdCho, x1), 50% (x1/2) or 25% (x1/4). In the liposomal preparations 
containing Nanotex these dilutions correspond to iron concentrations of 0.5 mg Fe/mL, 
0.25 mg Fe/mL and 0.125 mg Fe/mL. 
b) T2 values were determined at 1.5 Tesla (22 °C, Bruker Minispec, Rheinstetten, DE) using 





Figure 4. Fluorescence imaging of liposomes. In vitro (A, B) and in vivo (C) fluorescence images of liposomes loaded with nanoparticles and Rhodamine-100 as 
acquired with an IVIS-Lumina camera. A: Visible picture of the 96 well plate used as phantom, showing the columns of wells loaded with decreasing concentrations 
(top to bottom) of empty liposomes (white triangle), liposomes loaded with Rhodamine-100 (green triangle) and liposomes loaded with Rhodamine-100 and Nanotex 
(blue triangle). B: Fluorescence image of the same phantom using the Green Fluorescent Protein (GFP) filter. Note the increased fluorescence of the liposomes 
containing Rhodamine-100 only as compared to those containing Rhodamine-100 and Nanotex. C: In vivo images of a mouse injected with liposomes containing 
Rhodamine-100 and Nanotex (left side arrow), or liposomes containing Rhodamine-100 only (right side arrow). 




Figures 4A-B show results obtained in an in vitro 
fluorescence experiment, comparing in a multiwell 
plate, the fluorescence of empty liposomes (left track, 
white triangle), liposomes containing Rhodamine-100 
(central track, green triangle) and liposome containing 
Rhodamine-100 and Nanotex (right track, blue trian-
gle). Liposomes containing only Rhodamine-100 pre-
sent more intense fluorescence than liposomes con-
taining both Rhodamine-100 and Nanotex. This may 
be due to either or both of two circumstances. First, 
liposomes with Nanotex have to share their lumen 
space with Rhodamine-100 and one or more nano-
particles, resulting in a smaller intraluminal volume 
available for Rhodamine-100 accumulation and thus 
decreased intraluminal Rhodamine-100 concentra-
tion. Second, the Nanotex acrylic acid coating or its 
magnetite core could partially quench the fluores-
cence of Rhodamine-100.  
Figure 4C shows the results of a representative in 
vivo experiment in a mouse receiving an i.p. injection 
of liposomes labeled with Rhodamine-100 containing 
(left) or not (right) Nanotex. As in the in vitro experi-
ments, liposomes with Nanotex and Rhodamine-100 
(left) depict less quantum efficiency than liposomes 
with only Rhodamine-100, however, they still become 
observable by in vivo fluorescence (Figure 4C).  
Anti-inflammatory effects in vivo 
Mouse model of colonic inflammation 
We investigated the anti-inflammatory effects of 
liposomal preparations containing or not  ω-3 
PUFA-EE using a well-established model of colonic 
inflammation induced by dextran sulfate (sodium 
salt, DSS) administration [46, 55]. Untreated mice 
showed significant decreases in body weight, while 
mice treated with magnetoliposomes containing ω-3 
PUFA-EE reduced appreciably the loss of body 
weight along the treatment period (not shown), re-
vealing a potent anti-inflammatory effect of the for-
mulation. 
Figure 5 shows representative results of the ad-
ministration of saline (Figure 5A) or magnetolipo-
somes containing  ω-3 PUFA-EE (Figure 5B) to mice 
with rectal inflammation induced by DSS. Saline 
treated mice showed, as expected, clearly increased 
colonic wall thickness, easily observable in T1w images 
after Gd(III)DTPA enhancement. However, mice 
treated with magnetoliposomes containing ω-3 
PUFA-EE (Figure 5B) depicted a significant reduction 
in colonic wall thickness, revealing a prominent an-
ti-inflammatory effect of the theranostic formulation 
(Figure 5C-D). Notably, treatment with magnetolip-
osomes resulted, not only in a reduction of the rectal 
wall thickness, but in a significant darkening of this 
structure, a clear indication of the presence of mag-
netoliposomes in the inflamed region. 
C6 glioma mouse model 
We then examined the effects of magnetolipo-
somes containing or not ω-3 PUFA-EE in the inflam-
mation associated to glioma growth [8], using the C6 
glioma models. 
Figure 6 shows representative MRI T1w images of 
glioma evolution in a mouse treated with magne-
toliposomes containing (bottom panels) or not (upper 
panels) ω-3 PUFA-EE. Mice receiving magnetolipo-
somes without ω-3 PUFA-EE developed tumors to the 
same extent than controls receiving saline (not 
shown). However, mice receiving magnetoliposomes 
containing ω-3 PUFA-EE decreased notably the rate of 
glioma growth, and even increased the regression rate 
of the implanted gliomas. Table 4 compares the effects 
of administering magnetoliposomes containing ω-3 
PUFA-EE with control administrations of saline, 
empty liposomes or liposomes containing Nanotex 
only. The data show that the administration of mag-
netoliposomes containing ω-3 PUFA EE to mice 
bearing C6 tumors preserved the life of mice and in-
duced a decrease in tumor size, while the administra-
tion of saline, empty liposomes or magnetoliposomes 
containing only Nanotex did not preclude death of the 
animals nor reduced tumor growth. 
 
 
Table 4. Assesment of C6 tumor growth in mice receiving 
magnetoliposomes containing or not ω-3 PUFA-EE. 
Type of liposomal 
preparation injected a) 




% increase or de-
crease tumor size 
after treatment 
None, saline Mouse 1 12.72 18.87 +48.35% 
Mouse 2 38.89 131.82 +238.96% 
Empty Liposomes Mouse 5 13.46 26.92 +200,00% 
Mouse 6 18.37 76.23 +414,90% 
Nanotex Liposomes Mouse 9 15.756 27.5 +74.54% 
Mouse 10 14.473 20.212 +39.65% 
Mouse 11 8.298 13.787 +66.15% 
Nanotex + ω-3 
PUFA-EE Liposomes 
Mouse 13 12.624 2.825 -77.62% 
Mouse 14 6.07 0.396 -93.48% 
Mouse 15 8.952 0.347 -96.12% 
Mouse 16 24.377 10.179 -58.24% 
a) Liposomal preparations were administered i.v. through the tail vein fifteen days after C6 
cell implantation. 
b) Groups containing four mice at the time of treatment initiation were used in all condi-
tions. Only the mice surviving six days after treatment initiation are shown. 
c) Tumor size before treatment initiation. 
d) Tumor size after six days of treatment. 
c,d) Tumor area (mm2) reflects the area including the tumor and peripheral inflammation as 










Figure 5. Theranostic effects on colonic inflammation. T1w MRI of colonic inflammation in the rectal region of mice subjected to oral DSS administration for 
five days. A: untreated, B: treated with liposomes loaded with Nanotex and ω-3 PUFA-EE. Note the darker appearance of the rectum (arrows) from the mouse 
receiving magnetoliposomes loaded with Nanotex, revealing the presence of the nanoparticle. Wall thickness is illustrated by the orange line. Mean and standard 
deviation from measurements of rectal wall thickness (C) and wall area (D) are shown under the different conditions.  
 
 
Figure 6. Theranostic effects on tumoral inflammation and growth. Effect of magnetoliposomal preparations containing (bottom) or not (top) ω-3 PUFA-EE 
on the time course of glioma development after implantation of C6 cells in the caudate nucleus of the mouse brain. T2w images were acquired as indicated in methods. 
Left panels: (day 0), central panels (day 3), right panels (day 6). Note the accumulation of magnetoliposomes loaded with PUFA-EE revealed by the darkening of the 
tumoral lesion (arrow) and the eventual disappearance of the tumor six days after treatment. Table 4 summarizes the results obtained with animals surviving day 6. 




In addition to the MRI results, it becomes im-
portant to comment the external aspect and behavior 
of the mice. Mice with no treatment depicted bristly 
hair, decrease in motor activity and eventually hemi-
plegia and hemiparesis. Mice treated with liposomes 
with PUFA-EE did not present such symptoms, re-
vealing significantly better physiopathological state 
and sometimes regression of the tumor. 
Discussion 
We have presented a novel liposomal formula-
tion combining the therapeutic properties of ω-3 
PUFA-EE with the non-invasive multimodal imaging 
capabilities of Nanotex and Rhodamine-100, or the 
combination of both.  
Interestingly, the encapsulation of a superpara-
magnetic nanoparticle in a liposome results in differ-
ent relaxivity properties as compared to those of the 
free nanoparticle in suspension. These changes reflect 
necessarily modifications in the dynamics of the na-
noparticle-water interaction induced by the encapsu-
lation process. Indeed it would be expected that the 
encapsulation would decrease the interaction of the 
nanoparticle with the surrounding solvent water, be-
cause of the water impermeable liposomal membrane. 
These reduction effects are expected to occur mainly 
in the “outer sphere” relaxivity component, repre-
senting approximately 50% of the total relaxivity [56, 
57]. The approximately 30% decrease observed in r2 
follows closely enough this interpretation. However, a 
similar decrease would also be expected to occur in r1. 
This is not observed, indicating that the “outer 
sphere” effect is not the only determinant of the 
changes in relaxivity occurring after liposomal en-
capsulation. The r1 value shows, in contrast, an im-
portant increase, larger than an order of magnitude. 
The most probable cause of this increase is the re-
striction in the rotational movement of the nanoparti-
cle when present in the encapsulated lumen envi-
ronment. This may be imposed by, either an associa-
tion to the liposomal membrane, an increase in in-
traluminal microviscosity, or binding or interaction 
with neighboring nanoparticles, resulting in a slower 
tumbling time (τr in [57]). Indeed r1 and r2 have dif-
ferent determinants and behavior, as explained from 
their different Solomon-Bloembergen-Morgan equa-
tions [57-60], and it is not surprising that they respond 
differently to encapsulation. Moreover, r1 and r2, re-
flect the different time scales of T1 (s) and T2 (ms), 
making easier to understand that the events occurring 
in the ms range of T2, may be too fast to be detected in 
the second range time-scale of T1. In summary, the 
encapsulation of Nanotex in liposomes appears to 
decrease the “outer sphere” contribution, reflecting 
water diffusional limitations imposed by the liposo-
mal membrane, and a decrease in the tumbling time 
of the nanoparticle, revealing associations to the lip-
osomal membrane or to other nanoparticles in the 
lumen. In this respect, our results are similar to those 
previously described in literature [61-63].  
Present results on the encapsulation of ω-3 
PUFA-EE in liposomes complement and extend pre-
vious studies [64-66]. Our results show that it is pos-
sible to encapsulate significant amounts of lipid solu-
ble ω-3 PUFA-EE goticules in the liposomal lumen. 
This can be observed by the prominent 1H HRMAS 
resonances of liposomal suspensions containing the 
encapsulated fatty acids. The fact that these reso-
nances are observed reveals that the ω-3 PUFA-EE are 
mainly present as small, fast tumbling nanogoticules 
in the liposomal lumen. This is because ω-3 PUFA-EE 
nanogoticules pass easily through 300 kD filters, 
while the encapsulated ω-3 PUFA-EE goticules, are 
retained by the same filters together with the lipo-
somes. This finding is further confirmed by the fact 
that liposomal preparations containing encapsulated 
ω-3 PUFA-EE show the same ADC as the empty lip-
osomal preparations, revealing that the obstructions 
caused by the presence of ω-3 PUFA-EE goticules do 
not contribute appreciably to the average ADC of the 
suspension, dominated by the extraliposomal com-
partment. 
Our results provide also evidence that a signifi-
cant portion of the encapsulated ω-3 PUFA-EE is in-
serted within the liposomal bilayer. This is because 
the ω-3 PUFA-EE molecules inserted in the membrane 
adopt an α-helical structure around the olefinic pro-
tons [51], becoming rotationally immobilized and 1H 
HRMAS undetectable [52]. This circumstance is easily 
observed in resonance 20 (Figure 2C-2D), which 
shows full intensity in chloroform and roughly 30% 
intensity in water. This suggests that approximately 
70% of encapsulated ω-3 PUFA-EE becomes inserted 
in the membrane and 1H HRMAS invisible, while 30% 
forms 1H HRMAS observable nanogoticules in the 
liposomal lumen. 
The fluorescence study shows (Figure 4C) that 
the in vivo fluorescence signal from Rhodamine-100 
contained in magnetoliposomes is weak, superim-
poses on significant endogenous fluorescence and 
fades away progressively when the liposomes dis-
tribute later over a larger volume, as in colonic in-
flammation models. Moreover, the presence of Nan-
otex quenches considerably the fluorescence of Rho-
damine-100 (Figure 4B), making in vivo fluorescence 
detection not advisable for this agent under the pre-
sent conditions. Furthermore, in vivo fluorescence 
applications to the brain are largely limited by the 
presence of the skull, an opaque bone structure ham-
pering severely fluorescence detection. Taken togeth-




er, the reduced fluorescence of our nanoparticles and 
the presence of the skull, dissuaded further fluores-
cence applications to the brain. 
We show here also that the magnetoliposomal 
preparations containing Nanotex and ω-3 PUFA-EE 
present prominent anti-inflammatory activities 
against colonic inflammation and important anti-
tumoral effects against glioma while becoming sim-
ultaneously observable in vivo by MRI. 
Colonic inflammation is a disease associated to 
ulcerative colitis and Chron´s disease, two incurable 
pathologies at present. These are treated currently 
with conventional anti-inflammatory therapies, 
mainly free steroidal or immunosuppressant drugs, 
and eventually colonic resection by surgery [67]. The 
formulation proposed here has been shown to become 
therapeutically useful in animal models of DSS intox-
ication, adding a new, non-toxic formulation to the 
arsenal of therapeutic methods against these two 
morbid and prevalent diseases. 
Finally, our liposomal formulation encapsulating 
ω-3 PUFA-EE and Nanotex has demonstrated valua-
ble effects against glioma C6, slowing down prolifer-
ation and even inducing remission. These effects are 
due to the combination of Nanotex and the ω-3 
PUFA-EE since they are not induced by empty lipo-
somes or liposomes containing ω-3 PUFA-EE only. 
The precise mechanism of this unexpected coopera-
tive effect remains to be elucidated, but could proba-
bly involve a significant decrease in the 
pro-inflammatory component required for glioma 
proliferation or invasion and iron modulation of reac-
tive oxygen species [8, 9, 68]. 
In summary, present results illustrate the prop-
erties and use of a new nanotechnological formulation 
including one or more imaging agents and a thera-
peutic ω-3 PUFA-EE, useful in the treatment of the 
inflammatory component of colonic inflammation or 
glioma in animal models. A patent has been filed 
protecting the preparation, properties and use of this 
formulation [69]. 
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